The UK government has signed its fourth coronavirus vaccine deal, snapping up 60 million doses of an experimental shot being developed by Sanofi and GlaxoSmithKline.
Belgium’s ExeVir Bio is to accelerate development of a new treatment for COVID-19 based on llama antibodies, after a 23 million euro ($27 million) financing round.
Sanofi is to begin preparations in autumn to spin off its active ingredients business and is lining up a potential stock market launch by 2022, according to a press report.
LEO Pharma is gearing up to launch its eczema drug tralokinumab next year after submitting a filing to the FDA, as it bids to take on Sanofi’s class rival Dupixent.
US biotech Kymera Therapeutics has begun a strategic collaboration with Sanofi to develop and market several drugs tackling immune-inflammatory disease, which could be worth up to $2 billio
Sanofi has struck an exclusive rights deal with Dutch biotech Kiadis focused on combining modified natural killer cells with the French pharma’s blood cancer antibody Sarcl